El-Khoueiry, Anthony <br/><br/>
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jul 2013 
 - 53-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-013-2168-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Alanine--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Hepatocellular--blood<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Female<br/>Half-Life<br/>Hepatic Insufficiency--blood<br/>Humans<br/>Liver--drug effects<br/>Liver Neoplasms--blood<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Patient Dropouts<br/>Prodrugs--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Receptors, Fibroblast Growth Factor--antagonists & inhibitors<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Severity of Illness Index<br/>Triazines--administration & dosage